paraxanthine + aspirin + acetaminophen

paraxanthine + aspirin + acetaminophen is a patent-pending, fixed-dose combination oral formulation developed by Plopii for the acute treatment of migraine and tension headaches. Designed as a next-generation alternative to traditional caffeine-containing analgesics (such as Excedrin), this combination replaces caffeine with its primary active metabolite, paraxanthine. Paraxanthine acts as a selective adenosine receptor antagonist to provide vasoconstriction and enhance the pain-relieving effects of the co-formulated analgesics with a significantly reduced risk of jitters, anxiety, sleep disruption, and rebound headaches. Aspirin acts as an irreversible inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) to reduce inflammatory prostaglandins, while acetaminophen provides central analgesic and antipyretic effects. The drug is being developed under the FDA 505(b)(2) regulatory pathway.

Brand names

Plopii Migraine MedicationPlopii Migraine PillPlopii Headache Pill

Other names

paraxanthine + aspirin + paracetamolparaxanthine + acetylsalicylic acid + acetaminophenparaxanthine + acetylsalicylic acid + paracetamol